An Investigational New Drug Application (IND) is a request for authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans. A Pre-IND meeting provides an opportunity for open communication between a sponsor and the FDA, CBER, OCTGT to discuss planned IND content and to obtain advice from these centers.
Prior to this meeting, Regenicin submitted an information package describing the proposed content and format of the regulatory, Chemistry, Manufacturing, Controls (CMC), non-clinical product development work as well as a proposed clinical trial synopsis. This meeting will afford Regenicin the opportunity to gain further understanding of the FDA's expectations regarding these key sections of the IND.
"We are pleased to have begun discussions with the Agency regarding our proposed IND submission for NovaDerm®, and are very excited to have reached another milestone for Regenicin," said Randall McCoy, Chief Executive Officer of Regenicin.
Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey. For more information on Regenicin, Inc., as well as its technologies and products, please visit the company website at www.regenicin.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regenicin-inc-announces-scheduled-pre-ind-meeting-with-us-food-and-drug-administration-fda-for-its-new-autologous-cultured-skin-substitute-novaderm-300343499.html
SOURCE Regenicin, Inc.